Mesothelioma | Topics

FDA Approves Nivolumab Plus Ipilimumab for Previously Untreated Unresectable Malignant Pleural Mesothelioma
October 02, 2020

The agency approved the first and only immunotherapy treatment as a first-line therapy for adult patients with unresectable malignant pleural mesothelioma.

Nivolumab Plus Ipilimumab Improves OS in Malignant Pleural Mesothelioma
August 10, 2020

Data from the phase 3 CheckMate-743 trial showed a statistically significant overall survival benefit for patients with previously untreated, unresectable malignant pleural mesothelioma when treated with nivolumab plus ipilimumab.